# (19) World Intellectual Property Organization International Bureau





### (43) International Publication Date 1 August 2002 (01.08.2002)

## **PCT**

# (10) International Publication Number WO 02/059306 A3

- (51) International Patent Classification<sup>7</sup>: C12N 15/12, 15/11, 15/63, 1/21, 5/10, C07K 14/705, 16/28, A01K 67/027, C12Q 1/68, G01N 33/68
- (21) International Application Number: PCT/US01/42809
- (22) International Filing Date: 26 October 2001 (26.10.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 09/765,344 22 January 2001 (22.01.2001) U
- (71) Applicant: APPLERA CORPORATION [US/US]; 761 Main Avenue, Norwalk, CT 068559 (US).
- (72) Inventors: WEI, Ming-Hui; Celera Genomics, 45 West Gude Drive C2-4#21, Rockville, MD 20850 (US). KETCHUM, Karen, A.; Celera Genomics, 45 West Gude Drive C2-4#21, Rockville, MD 20850 (US). DI FRANCESCO, Valentina; Celera Genomics, 45 West Gude Drive C2-#21, Rockville, MD 20850 (US). BEASLEY, Ellen, M.; Celera Genomics, 45 West Gude Drive C2-4#21, Rockville, MD 20850 (US).
- (74) Agent: MILLMAN, Robert, A.; Genomics Celera, Chief Intellectual Property Counsel, 45 West Gude Drive C2-4#21, Rockville, MD 20850 (US).

- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

#### **Published:**

- with international search report
- (88) Date of publication of the international search report: 3 April 2003

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



2/059306 A3

(54) Title: ISOLATED HUMAN TRANSPORTER PROTEINS, NUCLEIC ACID MOLECULES ENCODING HUMAN TRANSPORTER PROTEINS, AND USES THEREOF

(57) Abstract: The present invention provides amino acid sequences acid sequences of peptides that are encoded by genes within the human genome, the transporter peptides of the present invention. The present invention specifically provides isolated peptide adnf nucleic acid molecules, methods of identifying orthlogs and paralogs of the transporter peptides, and methods of identifying modulators of the transporter peptides.

Intern al Application No PCT/US 01/42809

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 C12N15/12 C12N15/11 C07K14/705 C07K16/28 C12N1/21 G01N33/68 C12N5/10 C12N15/63 A01K67/027 C12Q1/68

According to International Patent Classification (IPC) or to both national classification and IPC

#### **B. FIELDS SEARCHED**

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EMBL, SEQUENCE SEARCH, EPO-Internal, WPI Data, PAJ, BIOSIS, MEDLINE, CHEM ABS Dat

	MENTS CONSIDERED TO BE RELEVANT		
Category °	Citation of document, with indication, where appropriate, of	the relevant passages	Relevant to claim No.
X	DATABASE EMBL 'Online! 9 April 2000 (2000-04-09) FAHRENKRUG S C ET AL: "114735 Sus scrofa cDNA 5', mRNA sequents Database accession no. AW6706 XP002193549	ence."	1-13
X	DATABASE EMBL 'Online! 11 September 1997 (1997-09-11 NCI-CGAP: "nn44h12.s1 NCI_CGAI sapiens cDNA clone IMAGE:1086 sequence." Database accession no. AA58219 XP002193550	P_GC5 Homo 791 3', mRNA	1-13
X Fu	rther documents are listed in the continuation of box C.	χ Patent family members are list	ed in annex.
Special of A docum cons 'E' earlier filing 'L' docum which citati 'O' docum other 'P' docum	rther documents are listed in the continuation of box C.  categories of cited documents:  ment defining the general state of the art which is not sidered to be of particular relevance r document but published on or after the international date nent which may throw doubts on priority claim(s) or h is cited to establish the publication date of another ion or other special reason (as specified) ment referring to an oral disclosure, use, exhibition or r means ment published prior to the international filing date but than the priority date claimed	To later document published after the interpretation or priority date and not in conflict with cited to understand the principle or invention  "X" document of particular relevance; the cannot be considered novel or can involve an inventive step when the  "Y" document of particular relevance; the cannot be considered to involve an document is combined with one or ments, such combination being ob in the art.  "8" document member of the same pate	nternational filing date ith the application but theory underlying the e claimed invention not be considered to document is taken alone e claimed invention inventive step when the more other such docu- vious to a person skilled
"A" documents of the constant	categories of cited documents:  ment defining the general state of the art which is not sidered to be of particular relevance or document but published on or after the international date of the cited to establish the publication date of another ion or other special reason (as specified) ment referring to an oral disclosure, use, exhibition or remeans ment published prior to the international filing date but	<ul> <li>'T' later document published after the interpretation or priority date and not in conflict work cited to understand the principle or invention</li> <li>'X' document of particular relevance; the cannot be considered novel or can involve an inventive step when the</li> <li>'Y' document of particular relevance; the cannot be considered to involve an document is combined with one or ments, such combination being obtain the art.</li> </ul>	nternational filing date ith the application but theory underlying the e claimed invention not be considered to document is taken alone e claimed invention inventive step when the more other such docu- vious to a person skilled
Special of A* documents of the filing the fi	categories of cited documents:  ment defining the general state of the art which is not sidered to be of particular relevance  r document but published on or after the international adate  ment which may throw doubts on priority claim(s) or his cited to establish the publication date of another ion or other special reason (as specified)  ment referring to an oral disclosure, use, exhibition or r means  ment published prior to the international filing date but than the priority date claimed	<ul> <li>"T" later document published after the incomprish or priority date and not in conflict with cited to understand the principle or invention.</li> <li>"X" document of particular relevance; the cannot be considered novel or can involve an inventive step when the</li> <li>"Y" document of particular relevance; the cannot be considered to involve an document is combined with one or ments, such combination being ob in the art.</li> <li>"&amp;" document member of the same pate</li> </ul>	nternational filing date ith the application but theory underlying the e claimed invention not be considered to document is taken alone e claimed invention inventive step when the more other such docu- vious to a person skilled

Intern al Application No
PCT/US 01/42809

C (Continu	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
Category °		Relevant to claim No.
A	DATABASE WPI Section Ch, Week 199932 Derwent Publications Ltd., London, GB; Class B04, AN 1999-378999 XP002193557 -& JP 11 146790 A (SUMITOMO SEIYAKU KK), 2 June 1999 (1999-06-02) SEQ ID NO: 1 abstract	1-23
Α	DATABASE EMBL 'Online! 15 July 1999 (1999-07-15) WOOD V ET AL: "PROBABLE SULFATE PERMEASE C3H7.02." Database accession no. 074377 XP002193551	1-23
X	WO 00 58473 A (CURAGEN CORP ;LEACH MARTIN (US); SHIMKETS RICHARD A (US)) 5 October 2000 (2000-10-05) SEQ ID NO: 3901; SEQ ID NO: 3902 claims 1-32	1-23
E,L	WO 01 81412 A (PE CORP NY) 1 November 2001 (2001-11-01) (L: Priority) the whole document	1-23
Ρ,Χ	WO 01 46258 A (INCYTE GENOMICS INC; AZIMZAI YALDA (US); KHAN FARRAH A (US); REDDY) 28 June 2001 (2001-06-28) SEQ ID NO: 17; SEQ ID NO: 44 page 25, line 25 - line 30; claims 1-28; examples 1-18 page 40, line 5 - line 9	1-23
L	DATABASE EMBL 'Online! 6 November 2001 (2001-11-06) OTA T ET AL: "Human polypeptide, SEQ ID NO: 4156." Database accession no. AAM93955 XP002193552 L document cited to provide information on the relevant sequence disclosed in	1-23
P,X	EP1130094A -& EP 1 130 094 A (HELIX RESEARCH INSTITUTE) 5 September 2001 (2001-09-05) claims 1-23/	1-23

Interr pal Application No
PCT/US 01/42809

INTERNAL CONCIDENTS TO SE BELEVANT	10703 01/42809
· ·	Relevant to claim No.
Citation of document, with indication, where appropriate, or the relevant passages	neievani to ciann ino.
DATABASE EMBL 'Online! 6 November 2001 (2001-11-06) 0TA T ET AL: "Human cDNA clone representative sequence, SEQ ID NO: 2278." Database accession no. AAK93818 XP002193553 L document cited to provide information on the relevant sequence disclosed in	1-23
-& EP 1 130 094 A (HELIX RESEARCH INSTITUTE) 5 September 2001 (2001-09-05) claims 1-23	1–23
DATABASE EMBL 'Online! 6 November 2001 (2001-11-06) 0TA T ET AL: "Human full-length cDNA, SEQ ID NO: 4155." Database accession no. AAK94922 XP002193554 L document cited to provide information on the relevant sequence disclosed in	1-23
-& EP 1 130 094 A (HELIX RESEARCH INSTITUTE) 5 September 2001 (2001-09-05) claims 1-23	1–23
DATABASE EMBL 'Online! 26 June 2001 (2001-06-26) OTA T ET AL: "Human protein sequence SEQ ID NO:16355." Database accession no. AAB94916	1-23
-& EP 1 074 617 A (HELIX RESEARCH INSTITUTE) 7 February 2001 (2001-02-07) claims 1-23	1-23
DATABASE EMBL 'Online! 26 June 2001 (2001-06-26) OTA T ET AL: "Human cDNA sequence SEQ ID NO:16354." Database accession no. AAH17049 XP002193556	1-23
-& EP 1 074 617 A (HELIX RESEARCH INSTITUTE) 7 February 2001 (2001-02-07) claims 1-23	1-23
SILBERG DEBRA G ET AL: "The Down Regulated in Adenoma (dra) Gene Encodes an Intestine-specific Membrane Sulfate Transport Protein." JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 270, no. 20, 1995, pages 11897-11902, XP002193548 ISSN: 0021-9258	
	6 November 2001 (2001-11-06) OTA T ET AL: "Human cDNA clone representative sequence, SEQ ID NO: 2278." Database accession no. AAK93818 XP002193553 L document cited to provide information on the relevant sequence disclosed in EP1130094A -& EP 1 130 094 A (HELIX RESEARCH INSTITUTE) 5 September 2001 (2001-09-05) claims 1-23  DATABASE EMBL 'Online! 6 November 2001 (2001-11-06) OTA T ET AL: "Human full-length cDNA, SEQ ID NO: 4155." Database accession no. AAK94922 XP002193554 L document cited to provide information on the relevant sequence disclosed in EP1130094A -& EP 1 130 094 A (HELIX RESEARCH INSTITUTE) 5 September 2001 (2001-09-05) claims 1-23  DATABASE EMBL 'Online! 26 June 2001 (2001-06-26) OTA T ET AL: "Human protein sequence SEQ ID NO:16355." Database accession no. AAB94916 XP002193555 -& EP 1 074 617 A (HELIX RESEARCH INSTITUTE) 7 February 2001 (2001-02-07) claims 1-23  DATABASE EMBL 'Online! 26 June 2001 (2001-06-26) OTA T ET AL: "Human cDNA sequence SEQ ID NO:16354." Database accession no. AAH17049 XP002193556 -& EP 1 074 617 A (HELIX RESEARCH INSTITUTE) 7 February 2001 (2001-02-07) claims 1-23  SILBERG DEBRA G ET AL: "The Down Regulated in Adenoma (dra) Gene Encodes an Intestine-specific Membrane Sulfate Transport Protein." JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 270, no. 20, 1995, pages 11897-11902, XP002193548

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: in part: 17,18

Claim 17 refers to a pharmaceutical composition comprising an agent that binds to any of the peptides of claim 2 without giving a true technical characterization of such an agent. The claim covers all compounds having this characteristic or property, whereas the application provides support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT for only a very limited number of such compounds, namely antibodies that selectively bind to a peptide of claim 2. In consequence, the scope of said claim is ambiguous and vague, and its subject-matter is not sufficiently disclosed and supported (Art. 5 and 6 PCT). An attempt is made to define the compound by reference to a result to be achieved. This lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Consequently, the search has been carried out for those parts of the claim which appear to be clear, supported and disclosed, namely those parts relating to antibodies that selectively bind to a peptide of claim 2.

The above comment also applies for claim 18.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

In \_\_itional application No. PCT/US 01/42809

Box I	Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)
This Inter	rnational Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
	Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
	Although claim 18 (in part) is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
	Claims Nos.:  in part: 17,18 because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
	see FURTHER INFORMATION sheet PCT/ISA/210
. $\Box$	
	Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box II	Observations where unity of invention is lacking (Continuation of item 2 of first sheet)
This Inter	rnational Searching Authority found multiple inventions in this international application, as follows:
1.	As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
	As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
	As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
	No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Remark	on Protest
	No protest accompanied the payment of additional search fees.

mation on patent family members

Intern al Application No
PCT/US 01/42809

Patent document cited in search report		Publication date		Patent family member(s)		Publication date
JP 11146790	Α	02-06-1999	NONE			
WO 0058473	Α	05-10-2000	AU	3774500	A	16-10-2000
			EP	1165784	A2	02-01-2002
			WO	0058473	<b>A</b> 2	05-10-2000
WO 0181412	Α	01-11-2001	<b></b> _US	2002019348	A1	14-02-2002
			ΑU	5380401	Α	07-11-2001
			WO	0181412	A2	01-11-2001
			WO	02059306	A2	01-08-2002
WO 0146258	Α	28-06-2001	AU	2736101		03-07-2001
			EP	1257578		20-11-2002
			WO	0146258	A2	28-06-2001 
EP 1130094	Α	05-09-2001	EP	1130094		05-09-2001
			JP	2002017375	Α	22-01-2002
EP 1074617	Α	07-02-2001	AU	6180800		19-02-2001
			ΑU	6180900		19-02-2001
			AU	6181000		19-02-2001
			ΑU	6181100		19-02-2001
			ΑU	6181200		19-02-2001
			AU	6181300		19-02-2001
			AU	6181400		19-02-2001
			AU	6181500		19-02-2001
			AU	6181600		19-02-2001
			AU	6315800		19-02-2001
			EP	1074617		07-02-2001
			EP	1205549		15-05-2002 08-02-2001
			MO	0109315 0109345		08-02-2001
			WO WO	0109345		08-02-2001
			WO	0109316		08-02-2001
			WO	0109349		08-02-2001
			WO	0109317		08-02-2001
			WO	0109318		08-02-2001
			WO	0109319		08-02-2001
			WO	0109340		08-02-2001
			WO	0109320		08-02-2001
			WO	0109321		08-02-2001
			WO	0109322		08-02-2001
			JP	2002171977		18-06-2002
			JP	2002171377		09-07-2002